Trial Profile

Sorafenib and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN):a Phase IB/II Trial.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Sorafenib (Primary)
Indications Head and neck cancer
Focus Adverse reactions

Most Recent Events

02 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
16 Feb 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
16 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com